Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 986340

Next Previous
Drug Profile

BMS 986340

Alternative Names: anti-CCR8 - Bristol-Myers Squibb; BMS-986340; ONO-7427

Latest Information Update: 18 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Ono Pharmaceutical
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CCR8 receptor antagonists; Regulatory T-lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours

Most Recent Events

  • 12 Nov 2025 Mayo Clinic plans a phase II trial for Adenocarcinoma (Combination therapy, Late-stage disease, First-line therapy, Metastatic disease) in USA (IV) (NCT07226856)
  • 09 Jun 2025 Bristol-Myers Squibb plans a phase II trial for Colorectal cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in USA (IV) (NCT07011550)
  • 23 Jan 2025 Phase-II clinical trials in Solid tumours (Combination therapy) in Japan (Parenteral), (Ono Pharmaceutical pipeline, January 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top